Volume 6.17 | May 5

Hematopoiesis News 6.17 May 5, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   HN on Twitter
 
TOP STORY
Leukemia Stem Cells in T-ALL Require Active Hif1α and Wnt Signaling
To address what role Wnt signaling may play in T-cell acute lymphoblastic leukemia (T-ALL), investigators utilized a stably integrated fluorescent Wnt reporter construct to interrogate endogenous Wnt signaling activity in vivo. [Blood] Abstract
Learn More: Standardized Tools for Cancer Research
 
PUBLICATIONS (Ranked by impact factor of the journal)
Altered Lymphopoiesis and Immunodeficiency in miR-142 Null Mice
To define the biological functions of microRNA-142 (miR-142), which is preferentially and abundantly expressed in immune cells, investigators created a mouse line with targeted deletion of this gene. [Blood] Abstract

Hypoxia Inducible Factor (HIF)-2α Accelerates Disease Progression in Mouse Models of Leukemia and Lymphoma but Is Not a Poor Prognosis Factor in Human AML
HIF-1α accumulation promotes hematopoietic stem cells quiescence and is necessary to maintain their self-renewal. Researchers investigated the role of HIF-2α in leukemia and lymphoma cells. HIF-2α expression was high in subsets of human and mouse leukemia and lymphoma cells whereas it was low in normal bone marrow leukocytes. [Leukemia] Abstract

The BMI1 Polycomb Protein Represses CyclinG2-Induced Autophagy to Support Proliferation in Chronic Myeloid Leukemia Cells
The BMI1 polycomb protein regulates self-renewal, proliferation and survival of cancer-initiating cells essentially through epigenetic repression of the CDKN2A tumor suppressor locus. Scientists demonstrated for the first time that BMI1 also prevents autophagy in chronic myeloid leukemia cell lines, to support their proliferation and clonogenic activity. [Leukemia] Abstract

Cannabinoid Receptor-2 Regulates Embryonic Hematopoietic Stem Cell Development via PGE2 and P-Selectin Activity
Using chemical and genetic approaches targeting cannabinoids (CB)-signaling in zebrafish, scientists showed that CB receptor (CNR)2, but not CNR1, regulates embryonic hematopoietic stem cell development. [Stem Cells] Abstract

Pbx3 and Meis1 Cooperate through Multiple Mechanisms to Support Hox-Induced Murine Leukemia
Hox homeobox transcription factors drive leukemogenesis efficiently only in the presence of Meis or Pbx proteins. The authors showed that Pbx3 and Meis1 need to dimerize to support Hox-induced leukemia and they analyzed the molecular details of this cooperation. [Haematologica] Abstract | Full Article

MicroRNA-124 Targets Tip110 Expression and Regulates Hematopoiesis
The authors identified a conserved microRNA-124 (miR-124) binding site on the Tip110 3′ untranslated region (3’UTR) and showed that Tip110 was down-regulated by miR-124 through its 3’UTR. They then examined the relationship among miR-124 and Tip110 expression and differentiation of human cord blood CD34+ cells. [Stem Cells Dev] Abstract

CLINICAL RESEARCH

Bendamustine, Bortezomib and Prednisone for the Treatment of Newly Diagnosed Multiple Myeloma Patients: Results of a Prospective Phase II Spanish/Pethema Trial
Sixty newly diagnosed myeloma patients received bendamustine plus bortezomib and prednisone consisting of one cycle of bortezomib twice per week for six weeks, plus bendamustine and prednisone. [Haematologica] Abstract | Full Article

Second Allogeneic Transplantation Using Unrelated Cord Blood for Relapsed Hematological Malignancies after Allogeneic Transplantation
Investigators analyzed the results of second allogeneic stem cell transplantation using single-unit unrelated cord blood in 34 adult patients with relapsed hematological malignancies after initial allogeneic stem cell transplantation in their institution. [Leuk Lymphoma] Abstract

Register Now for Live Webinar: New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells
 
REVIEWS
Mesenchymal Stromal Cell Therapy in Hematology: From Laboratory to Clinic and Back Again
The authors focus on cell therapy applications for mesenchymal stromal cells (MSC) in hematology. In this domain MSC are used for the treatment or prevention of graft versus host disease, support of hematopoiesis or repair of tissue toxicities after hematopoietic cell transplantation. They critically review the accumulating clinical data and elaborate on complications that might arise from treatment with MSC. [Stem Cells Dev] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Your Favorite Immunology Newsletters Are Now on Facebook! Like Us Today!
 
INDUSTRY NEWS
BioLineRx Initiates Expansion Stage of Phase II Clinical Trial for Novel Treatment for Acute Myeloid Leukemia
BioLineRx Ltd. announced successful completion of the dose escalation stage of its ongoing Phase II study of BL-8040, and commencement of the expansion stage at the optimal dose of this novel treatment for acute myeloid leukemia. [BioLineRx Ltd.] Press Release

Generon Received US FDA Clearance to Initiate Phase IIa Study with F-652, a First-in-Class Biologic, to Treat Patients with Acute GvHD
Generon Corporation announced that it received US FDA clearance of the IND for a Phase IIa study, entitled “Recombinant Human Interleukin-22-IgG2-Fc (F-652) in Combination with Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease in Hematopoietic Stem Cell Transplantation Recipients.” [Generon (Shanghai) Corporation Ltd.] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 25th Regional Congress of the International Society for Blood Transfusion (ISBT)
June 27-July 1, 2015
London, United Kingdom

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Scientist – Hematopoiesis (University of Oxford)

NEW Postdoctoral Positions – Regulation of Normal and Malignant Hematopoiesis (Karolinska Institute)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Researcher – Hematopoietic Stem Cell Physiology and Pathophysiology (International Research Center for Medical Sciences)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford-Burnham Medical Research Institute)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (University of Leuven)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Postdoctoral Fellow – Hematopoietic Stem Cell Research (Lund University)

Postdoctoral Research Fellow – Stem Cell/Hematopoiesis Research (BloodCenter of Wisconsin)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us